Literature DB >> 24426345

Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic Acid and high flux dialysis.

Suthanthira Kannan Ramamoorthy1, R Hephziba1.   

Abstract

High dose methotrexate infusion has become the standard of care in pediatric and adult acute lymphoblastic leukemia management. Adequate hydration, alkalinization of urine and optimal folinic acid rescue are the key factors in the prevention of toxicity. The development of acute renal failure after high dose methotrexate infusion is very rare, albeit a few cases have been reported in literature. Various options have been available in addition to high dose folinic acid rescue, such as ultra filtration dialysis, continuous extracorporeal therapy, thymidine and Glucarpidase infusion to directly counter act excess methotrexate. In a developing country with limited reserves, managing a patient who develops acute renal failure immediately after high dose methotrexate is a nightmare without Glucarpidase. We report here a case that has been managed successfully with intensive supportive measures alone.

Entities:  

Year:  2012        PMID: 24426345      PMCID: PMC3636355          DOI: 10.1007/s12288-011-0143-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  9 in total

1.  Reduced methotrexate clearance and renal impairment in a boy with osteosarcoma and earlier undetected autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Martin Alberer; Julia Hoefele; Carsten Bergmann; Steffen Hartrampf; Jutta Hilberath; Ingo Pawlita; Michael H Albert; Marcus R Benz; Lutz T Weber; Irene Schmid
Journal:  J Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.289

Review 2.  Understanding and managing methotrexate nephrotoxicity.

Authors:  Brigitte C Widemann; Peter C Adamson
Journal:  Oncologist       Date:  2006-06

3.  High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.

Authors:  Norman Jaffe; Richard Gorlick
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

4.  Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.

Authors:  H T Abelson; W Ensminger; A Rosowsky; J Uren
Journal:  Cancer Treat Rep       Date:  1978-10

5.  Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.

Authors:  Rita Turello; Katharina Rentsch; Ermindo Di Paolo; Maja Beck Popovic
Journal:  Pediatr Blood Cancer       Date:  2008-01       Impact factor: 3.167

6.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

7.  High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.

Authors:  Brigitte C Widemann; Frank M Balis; Beate Kempf-Bielack; Stefan Bielack; Charles B Pratt; Stefano Ferrari; Gaetano Bacci; Alan W Craft; Peter C Adamson
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

8.  Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment.

Authors:  Takeshi Isoda; Sukeyuki Ito; Michiko Kajiwara; Masayuki Nagasawa
Journal:  Pediatr Int       Date:  2007-12       Impact factor: 1.524

9.  Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.

Authors:  A Mary Vilay; Bruce A Mueller; Hilary Haines; Jeffery A Alten; David J Askenazi
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

  9 in total
  6 in total

1.  Role of Salvia officinalis Silver Nanoparticles in Attenuation Renal Damage in Rabbits Exposed to Methotrexate.

Authors:  M A Saud; N A Saud; M A Hamad; L Farhan Gar
Journal:  Arch Razi Inst       Date:  2022-02-28

2.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

3.  Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL).

Authors:  Manjusha Sajith; Atmaram Pawar; Vibha Bafna; Sandip Bartakke; Kannan Subramanian; Neela Vaidya
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-06       Impact factor: 0.900

4.  Chronic Kidney Disease in Patients with Psoriasis -A Hospital Based Cross Sectional Study.

Authors:  P Seena; Sandhya George; Beena Narayanan; M Poornimamba; C V Shabna; Ajith Gopinath
Journal:  Indian Dermatol Online J       Date:  2021-11-22

Review 5.  Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies.

Authors:  Doron Feinsilber; Roberto J Leoni; Duminda Siripala; Julianne Leuck; Katrina A Mears
Journal:  Cureus       Date:  2018-01-08

6.  Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study.

Authors:  Berna Demiralp; Lane Koenig; Jaya Kala; Chaoling Feng; Elizabeth G Hamlett; Marie Steele-Adjognon; Suzanne Ward
Journal:  Clinicoecon Outcomes Res       Date:  2019-02-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.